GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, multi-center study of GM-CT-01 which has been shown to increase the
anti-tumor activity of 5-fluorouracil (5-FU) in mice. 5-FU is a chemotherapy drug commonly
used in cancer patients. In this Phase II study, patients with colon cancer which has spread,
despite treatment with approved therapies, will receive GM-CT-01 plus 5-FU in monthly cycles
for at least 2 cycles or until their disease progresses.